Had experienced documented progressive disease after expanded clinical benefit
Extended Maintenance
Received ipilimumab at any dose in a parent study
Achieved expanded clinical benefit at the time of entry to current study
Follow-up:
Received ipilimumab at any dose in a closing parent study
Deemed ineligible for reinduction or extended maintenance treatment or refused treatment as reinduction or extended maintenance at the time of screening in the current study, but consented to follow-up
You may not be if
Prior treatment with a CD137 agonist or a cytotoxic T-lymphocyte antigen 4 inhibitor or agonist, other than ipilimumab
